Enclomiphene

25mg 100 tablets

Enclomiphene is a research‑grade selective estrogen receptor modulator (SERM) investigated for its ability to stimulate endogenous testosterone while preserving sperm production in hypogonadal males. This material is for qualified laboratory research use only and is not approved by the FDA for any indication or for human or veterinary administration.

Enclomiphene is the trans‑isomer component of clomiphene citrate, acting as a selective estrogen receptor antagonist at the hypothalamic–pituitary level to disrupt estrogen’s negative feedback on the HPG axis. By blocking estrogen receptors centrally, enclomiphene increases gonadotropin‑releasing hormone (GnRH), which elevates luteinizing hormone (LH) and follicle‑stimulating hormone (FSH), driving testicular testosterone production in preclinical and clinical models. Unlike exogenous testosterone therapy, which can suppress spermatogenesis, enclomiphene has been studied as an oral option that raises serum testosterone while maintaining or improving sperm parameters in men with functional hypogonadism.

Key research themes
• Endogenous testosterone restoration in functional or secondary hypogonadism models.
• Preservation of fertility metrics compared with traditional testosterone replacement.
• Differentiated profile versus mixed‑isomer clomiphene, with similar testosterone gains and lower estradiol elevations and adverse events in published cohorts.
• Oral SERM strategy as a potential alternative to transdermal testosterone gel in specific research populations.